Here's Won't Touch Teva: Why I Pass on the Generic Giant
Teva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Discover effective wealth growth strategies for beginners that pave the way to financial success. Start learning and investing wisely now.
23,833 articlesTeva Pharmaceuticals sits at a crossroads of debt, generics, and a shifting pricing landscape. Here's why I won't tou...
Major forecasters are revising their 2026 outlooks, signaling a housing market forecasts flip that could shift timing...
Veteran investor Jeremy Grantham warns that U.S. stock valuations have grown extremely stretched, signaling a potenti...
You might have retirement savings you don’t realize exist. Old 401(k)s, IRAs, and other accounts can quietly sit unus...
The Nasdaq plans a 15‑session fast-track entry for AI leaders into the Nasdaq 100, while the S&P considers shortening...
Meta's plan to monetize AI infrastructure roils cloud peers, sending private-market signals lower for CoreWeave and N...
As Archer Aviation moves toward broader commercial programs, investors need a clear view of 2025 earnings drivers. Th...
Nvidia is expanding beyond chips by taking stakes in fellow AI players. This strategic move could quietly power growt...
As data centers expand and AI workloads surge, the tech industry faces a critical power reliability challenge. This a...
Geopolitical headlines drove a rush to buy the dip, yet the rebound failed to materialize for many investors. The epi...
A recent SEC filing shows Pale Fire Capital expanding its Ziff Davis position. This move offers clues about hedge fun...
Small-cap stocks have staged a surprising comeback as the market navigates a higher-for-longer rate environment. Inve...